Compare AST SpaceMobile Inc (ASTS) vs Novartis AG (NVS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AST SpaceMobile Inc vs Novartis AG — how do they compare? AST SpaceMobile Inc trades at $72.37 (market cap $21.90B), while Novartis AG trades at $153.86 (market cap $293.03B). The key difference: Novartis AG is far larger — about 13.4× AST SpaceMobile Inc's market cap, and Novartis AG pays a 3.08% dividend while AST SpaceMobile Inc pays none. Which is the better fit depends on your goals.
| ASTS | NVS | |
|---|---|---|
Market Cap | $21.90B | $293.03B |
Sector | Media | Health |
52-Week High | $133.09 | $168.62 |
52-Week Low | $36.91 | $113.50 |
Enterprise Value | $21.87B | $333.05B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASTS trades at $73.32, down 0.76% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported revenue of $70.92 million in 2025 but sustained a net loss of $341.94 million, missing earnings expectations for three consecutive quarters. Recent news highlights potential in defense communications via satellite technology, though competition with SpaceX remains a focal point.
The outlook is speculative with high execution risk; analyst consensus is divided with a $90.33 price target. Investment opportunity hinges on successful satellite deployment and partnership execution, but persistent losses and intense competition pose significant downside risks for shareholders.
Novartis (NVS) trades at $154.05, down 0.37% with a bullish technical signal supported by moving averages. The company demonstrates strong profitability with 75.38% gross margins and 35.21% ROE, though recent Q1 2026 earnings missed expectations. Recent developments include the $1.5B Myricx Bio acquisition expanding oncology capabilities and positive clinical trial results for neuromuscular and skin disorder treatments.
Investment outlook remains favorable with analyst consensus leaning hold (68%) amid solid fundamentals. Key opportunities include pipeline expansion through acquisitions, while risks involve execution of recent deals and competitive pressures in pharmaceuticals. The stock presents a balanced profile for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AST SpaceMobile Inc
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.
Read more on ASTS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
